Warrant TO1

Warrants of series TO1

In connection to the directed issue that was completed in September 2020 a total of 34,519,281 warrants of series TO1 was issued.

The subscription period for exercise of the warrants of series TO1 took place from September 15, 2021, up to and including September 29, 2021. The subscription price per share for exercising the warrants of series TO1 was set to SEK 2.85.

In total, 33,442,470 warrants of series TO1 were exercised for subscription of 33,442,470 shares of series B, meaning that approximately 96.9 percent of all outstanding warrants of series TO1 were exercised for subscription of shares.

“It is very rewarding to see the high subscription rate that was achieved. The successful share issue shows that the shareholders have a lot of confidence in Cereno, which may be due to a combination of all the important milestones that were achieved during the past twelve months and the big potential ahead which could be realized from the Company’s development as we move forward with our promising programs”, says Sten Sörensen, CEO of Cereno Scientific. “We are currently working at full speed with implementing our clinical phase II study with CS1 in pulmonary arterial hypertension and there is also a lot of activity in our two preclinical programs which are being pursued in collaboration with University of Michigan. The capital that we are now receiving makes it possible to run these development programs with full force and allows us to continue to build Cereno’s technological platform which has the potential to offer better treatments for common and rare cardiovascular diseases, where there are large unmet needs”.

Documents

Bilaga B - Optionsvillkor TO1

Read here (in Swedish only) >

Letter to warrant holders

Read here (in Swedish only) >